IMPACT OF FLASH GLUCOSE MONITORING ON GLYCEMIC CONTROL AND QUALITY OF LIFE IN ADULTS WITH TYPE 1 DIABETES: A REAL WORLD STUDY.

Session Name
GLUCOSE SENSORS
Session Type
E-POSTER VIEWING (EXHIBITION HOURS)
Date
20.02.2020, Thursday
Session Time
09:30 - 15:30
Channel
E-Poster Area
Lecture Time
09:30 - 09:30
Presenter
  • María Piedra, Spain
Authors
  • Ricardo Batanero, Spain
  • Angela Gonzalez, Spain
  • María Piedra, Spain
  • Lourdes Aizpeolea, Spain
  • ASUNCION Gomez, Spain
  • CASTAÑAR Garcia, Spain
  • FERNANDO Pazos, Spain
  • Luis A. Vazquez, Spain
  • Coral Montalban, Spain

Abstract

Background and Aims

Flash Glucose Monitoring (FGM) is associated with significant improvements in HbA1c but the impact on quality of life (QoL) stays unknown. This study aimed to examine the effect of FGM on glycemic control and QoL in a cohort of adults with Type 1 Diabetes.

Methods

We undertook a prospective, real-world, case-control study with a six-month follow up involving patients treated with multiple insulin injections. Individuals who started with a FGM system for the first time (cases) were compared with those who were using it previously (controls). The end points were metabolic outcomes and the scores of QoL questionnaires (EsDQUOL and Hypoglycemia Fear Survey-HFS-).

Results

41 patients were included in the case group ( 61% women, mean age: 42,8 ±12,1 years, diagnosed for 1-53 years, mean HbA1c: 7,6% ± 1,2) and 23 patients in the control group (52% women, mean age: 42,8 ± 16,1 years, diagnosed for 1-40 years, mean HbA1c: 7,1% ± 0,7). EsDQUOL score improved in the case group (96,53 vs 83,58 after 6 months; p=0,005) but not in the control group. There were no significant differences in HbA1c or in the rest of the analyzed outcomes (Body Mass Index, dose of insulin/kg, rapid insulin percentage, severe hypoglycemias and HFS score).

Conclusions

FGM could improve QoL of patients with Type 1 Diabetes. Additional studies with a larger number of patients and a longer follow up are probably needed to observe changes in metabolic outcomes.

Hide